Celgene eyes earlier US filing for apremilast in psoriatic arthritis after positive data
This article was originally published in Scrip
Celgene has shortened the timeframe in which it plans to submit a new drug application (NDA) to the US FDA for apremilast in the treatment of psoriatic arthritis (PsA) based on positive topline results from the last two of three Phase III clinical trials for its novel, oral small molecule inhibitor of phosphodiesterase 4 (PDE4).
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.